PPF Group

ClearBank® is the UK’s first clearing bank in more than 250 years. They plan to create a new level of open competition and transparency within the UK market. Their state-of-the-art technology transforms the clearing bank experience, making payments faster, cheaper and more efficient for everyone.

NBE-Therapeutics is a privately owned Swiss, Basel-based biotech company that was founded in 2012. It is dedicated to developing cancer therapies to increase survival and improve the quality of life for cancer patients worldwide. The company’s immune-stimulatory therapies are based on a proprietary, highly differentiated Antibody-Drug Conjugate platform. Its ADC platform creates potent and safe immune-stimulatory ADCs with an anthracycline payload, not only directly targeting tumor cells but also inducing a long-lasting immunological anti-tumor effect.

Cellestia Biotech AG, a biopharmaceutical company, engages in the development of anti-cancer drugs that modulate the NOTCH signaling pathway for the treatment of oncology and immunological disorders. The company focuses on developing its lead development candidate CB-103, which is a small molecule drug candidate. Its CB-103 is a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The company also focuses on developing NOTCH-specific PD biomarkers and diagnostics for patient selection. Cellestia Biotech AG was founded in 2014 and is headquartered in Basel, Switzerland with an additional location in Lausanne.

Central European Media Enterprises Ltd. (CME) is a media and entertainment company operating broadcast, content and new media businesses in Central and Eastern Europe. CME operates in three business segments: Broadcast, Media Pro Entertainment and New Media. The Company operates mainly in Bulgaria, Croatia, the Czech Republic, Romania, the Slovak Republic and Slovenia. It also has broadcast operations in Moldova and content distribution operations in Hungary. CME’s broadcast segment consists of 36 television channels reaching an aggregate of approximately 50 million people primarily in six countries. The Company’s Media Pro Entertainment is organized into two businesses: production and distribution. As of December 31, 2012, CME owned and operated over 70 Websites across its markets and it had launched its video-on-demand service, Voyo.

MaveriX is a globally-orientated biotechnology company focused on the discovery, development, and commercialization of targeted small-molecule cancer chemo-immunotherapies.Their technology approach leverages unexploited insights into cancer and immune cell metabolism within the tumor microenvironment which are common to all cancers.

Autolus Therapeutics plc is a clinical-stage biopharmaceutical company based in London, United Kingdom, focused on developing T cell therapies for various types of cancer, including hematological malignancies and solid tumors. Founded in 2014, the company has an innovative pipeline that includes AUTO1 and AUTO3 targeting B cell malignancies, AUTO2 for multiple myeloma, and AUTO4 and AUTO5 aimed at T cell lymphoma, as well as AUTO6 and AUTO7 for solid tumors. Autolus specializes in T cell programming and manufacturing technology, which it believes will provide a competitive edge in the advancement of next-generation therapies.

ClearBank® is the UK’s first clearing bank in more than 250 years. They plan to create a new level of open competition and transparency within the UK market. Their state-of-the-art technology transforms the clearing bank experience, making payments faster, cheaper and more efficient for everyone.

Cellestia Biotech AG, a biopharmaceutical company, engages in the development of anti-cancer drugs that modulate the NOTCH signaling pathway for the treatment of oncology and immunological disorders. The company focuses on developing its lead development candidate CB-103, which is a small molecule drug candidate. Its CB-103 is a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The company also focuses on developing NOTCH-specific PD biomarkers and diagnostics for patient selection. Cellestia Biotech AG was founded in 2014 and is headquartered in Basel, Switzerland with an additional location in Lausanne.

NBE-Therapeutics is a privately owned Swiss, Basel-based biotech company that was founded in 2012. It is dedicated to developing cancer therapies to increase survival and improve the quality of life for cancer patients worldwide. The company’s immune-stimulatory therapies are based on a proprietary, highly differentiated Antibody-Drug Conjugate platform. Its ADC platform creates potent and safe immune-stimulatory ADCs with an anthracycline payload, not only directly targeting tumor cells but also inducing a long-lasting immunological anti-tumor effect.

Culture Trip is a global tech startup that inspires people to explore the world’s culture and creativity through innovative technology and a global network of local content creators. It was founded in London in 2011 by former academic psychiatrist Dr Kris Naudts and was named by Forbes as one of five fast-growing UK companies to watch. Everyone working with Culture Trip is driven by a shared vision: to bring the world to everyone and in doing so to bring us all closer together. With offices in London, NYC and Tel Aviv and a global hub of editorial contributors hailing from all over the world, they are passionate about producing inspiring, local content and recommendations that enhance people’s lives.

NOVA Broadcasting Group offers television and news broadcasting services.

ClearBank® is the UK’s first clearing bank in more than 250 years. They plan to create a new level of open competition and transparency within the UK market. Their state-of-the-art technology transforms the clearing bank experience, making payments faster, cheaper and more efficient for everyone.

Cellestia Biotech AG, a biopharmaceutical company, engages in the development of anti-cancer drugs that modulate the NOTCH signaling pathway for the treatment of oncology and immunological disorders. The company focuses on developing its lead development candidate CB-103, which is a small molecule drug candidate. Its CB-103 is a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The company also focuses on developing NOTCH-specific PD biomarkers and diagnostics for patient selection. Cellestia Biotech AG was founded in 2014 and is headquartered in Basel, Switzerland with an additional location in Lausanne.

NBE-Therapeutics is a privately owned Swiss, Basel-based biotech company that was founded in 2012. It is dedicated to developing cancer therapies to increase survival and improve the quality of life for cancer patients worldwide. The company’s immune-stimulatory therapies are based on a proprietary, highly differentiated Antibody-Drug Conjugate platform. Its ADC platform creates potent and safe immune-stimulatory ADCs with an anthracycline payload, not only directly targeting tumor cells but also inducing a long-lasting immunological anti-tumor effect.

Culture Trip is a global tech startup that inspires people to explore the world’s culture and creativity through innovative technology and a global network of local content creators. It was founded in London in 2011 by former academic psychiatrist Dr Kris Naudts and was named by Forbes as one of five fast-growing UK companies to watch. Everyone working with Culture Trip is driven by a shared vision: to bring the world to everyone and in doing so to bring us all closer together. With offices in London, NYC and Tel Aviv and a global hub of editorial contributors hailing from all over the world, they are passionate about producing inspiring, local content and recommendations that enhance people’s lives.

Cytune is a private company developing a broad portfolio of novel immunotherapeutic agents to treat primarily cancer. Cytune’s hedge relies on a proprietary scientific breakthrough in immunology: effective form of a major human immunocytokine: trans-presentation mechanism of a critical immune factor: IL-15 Cytune’s proprietary most advanced proprietary compound, CYP 0150, is a human interleukin-15 uniquely linked to its effector. Cytune is further developing conjugated monoclonal antibodies linked to CYP 0150. Cytune was founded in 2007 and is managed by Dr. David Bechard, a successful serial biotech entrepreneur and Dr. Yannick Jacques, Director of Public Research at the Inserm (National Institute for Health and Medical Research)

ClearBank® is the UK’s first clearing bank in more than 250 years. They plan to create a new level of open competition and transparency within the UK market. Their state-of-the-art technology transforms the clearing bank experience, making payments faster, cheaper and more efficient for everyone.

Cytune is a private company developing a broad portfolio of novel immunotherapeutic agents to treat primarily cancer. Cytune’s hedge relies on a proprietary scientific breakthrough in immunology: effective form of a major human immunocytokine: trans-presentation mechanism of a critical immune factor: IL-15 Cytune’s proprietary most advanced proprietary compound, CYP 0150, is a human interleukin-15 uniquely linked to its effector. Cytune is further developing conjugated monoclonal antibodies linked to CYP 0150. Cytune was founded in 2007 and is managed by Dr. David Bechard, a successful serial biotech entrepreneur and Dr. Yannick Jacques, Director of Public Research at the Inserm (National Institute for Health and Medical Research)